Sanofi-Aventis agreed to pay biotech firm Alopexx Pharmaceuticals as much as $375 million for rights to co-develop a monoclonal antibody for treating E. coli, Staphylococcus aureus and other infections. The French drugmaker will have the option to license the product, which will be in Phase I trials next year.

Related Summaries